TECARTUS® is the first and only FDA-approved CAR T-cell therapy for adult patients with relapsed or refractory mantle cell lymphoma1,2

87% ORR (n=52/60)2

DEEP

CR: 62% (n=37/60)2

DURABLE

The median duration of response was not reached at a median study follow-up of 12.3 months2,4

RAPID

1 month median time to response (range: 0.8–3.1 months)2

BTKi=Bruton’s tyrosine kinase inhibitor; CAR=chimeric antigen receptor; CR=complete response; DOR=duration of response; ORR=objective response rate; PFS=progression-free survival.

References: 1. U.S. FDA approves Kite’s TECARTUS™, the first and only CAR T treatment for relapsed or refractory mantle cell lymphoma. News release. Kite, a Gilead Company; July 24, 2020. Accessed January 7, 2021. https://www.businesswire.com/news/home/20200724005428/en/U.S.-FDA-Approves-Kite%E2%80%99s-Tecartus%E2%84%A2-CAR-Treatment 2. TECARTUS® (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2021. 3. Data on file [1]. Kite Pharma, Inc; 2020. 4. Data on file [2]. Kite Pharma, Inc; 2020. 5. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas. V.2.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed February 23, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org. 6. Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle cell lymphoma. N Engl J Med. 2020;382(14):1331-1342.